QuidelOrtho Corp
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last report3 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
QuidelOrtho Corp
13.90
−0.13 · −0.93%
Same SIC code · 6
Same SEC industry code: Idexx Laboratories Inc, Lantheus Holdings, Inc., Celldex Therapeutics, Inc. and 3 more; of QuidelOrtho Corp's 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Idexx Laboratories Inc, Lantheus Holdings, Inc., Celldex Therapeutics, Inc. and 3 more; of QuidelOrtho Corp's 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Feb 19 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 19 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $196.2M | 13.39% | +7.21% |
| FMR | $129.0M | 8.80% | +11.72% |
| Newtyn | $116.0M | 7.92% | +45.33% |
| Vanguard Portfolioindex-like | $72.4M | 4.94% | +2.57% |
| Neuberger Berman | $62.1M | 4.24% | +130.96% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $196.2M | 13.39% | +7.21% |
| FMR | $129.0M | 8.80% | +11.72% |
| Newtyn | $116.0M | 7.92% | +45.33% |
| Vanguard Portfolioindex-like | $72.4M | 4.94% | +2.57% |
| Neuberger Berman | $62.1M | 4.24% | +130.96% |
Bull2
Bear2
Tall tick = annual report · Source: EDGAR
Expected move
Inputsspot 14.03exp Nov 20ATM strike 15ATM straddle 3.35IV 127%